Inspire Medical Systems Q3 2025 Earnings Report

Inspire Medical Systems EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.11
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Inspire Medical Systems Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $220.39 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Inspire Medical Systems Announcement Details

• Quarter: Q3 2025
• Date: 11/3/2025
• Time: After Market Closes
• Conference Call Date: Monday, November 3, 2025
• Conference Call Time: 5:00PM ET

Inspire Medical Systems (NYSE:INSP) is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve. The device received FDA approval in 2014 and has since obtained CE mark authorization for marketing in Europe. Inspire collaborates with a network of accredited sleep centers and specialized physicians to identify eligible patients and provide training, support and follow-up care.

Founded in 2007 and headquartered in Golden Valley, Minnesota, Inspire Medical Systems serves markets across North America and Europe, with ongoing efforts to expand its commercial footprint in select international regions. The company is led by President and Chief Executive Officer Michael A. Moulder, supported by a management team with deep expertise in medical devices, regulatory affairs and commercial operations. Inspire remains focused on advancing its technology platform through clinical research, product enhancements and expanded physician education programs.